PMC:7346000 / 7640-7926 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T21","span":{"begin":21,"end":25},"obj":"Body_part"},{"id":"T22","span":{"begin":238,"end":251},"obj":"Body_part"}],"attributes":[{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma86583"}],"text":"The possibility that IL-1 and related pro-inflammatory pathways could serve as therapeutic targets was demonstrated by the favorable responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis treated with the interleukin-1 receptor antagonist anakinra [25]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"234","span":{"begin":21,"end":25},"obj":"Gene"},{"id":"241","span":{"begin":162,"end":170},"obj":"Species"},{"id":"247","span":{"begin":153,"end":161},"obj":"Disease"},{"id":"248","span":{"begin":176,"end":220},"obj":"Disease"}],"attributes":[{"id":"A234","pred":"tao:has_database_id","subj":"234","obj":"Gene:3552"},{"id":"A241","pred":"tao:has_database_id","subj":"241","obj":"Tax:9606"},{"id":"A247","pred":"tao:has_database_id","subj":"247","obj":"MESH:C000657245"},{"id":"A248","pred":"tao:has_database_id","subj":"248","obj":"MESH:D051359"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The possibility that IL-1 and related pro-inflammatory pathways could serve as therapeutic targets was demonstrated by the favorable responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis treated with the interleukin-1 receptor antagonist anakinra [25]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T83","span":{"begin":153,"end":161},"obj":"Disease"},{"id":"T84","span":{"begin":176,"end":220},"obj":"Disease"},{"id":"T85","span":{"begin":186,"end":220},"obj":"Disease"}],"attributes":[{"id":"A83","pred":"mondo_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0015542"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0015540"}],"text":"The possibility that IL-1 and related pro-inflammatory pathways could serve as therapeutic targets was demonstrated by the favorable responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis treated with the interleukin-1 receptor antagonist anakinra [25]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T61","span":{"begin":238,"end":251},"obj":"http://purl.obolibrary.org/obo/PR_000001091"}],"text":"The possibility that IL-1 and related pro-inflammatory pathways could serve as therapeutic targets was demonstrated by the favorable responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis treated with the interleukin-1 receptor antagonist anakinra [25]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T36","span":{"begin":21,"end":23},"obj":"Chemical"},{"id":"T38","span":{"begin":261,"end":271},"obj":"Chemical"}],"attributes":[{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A37","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"}],"text":"The possibility that IL-1 and related pro-inflammatory pathways could serve as therapeutic targets was demonstrated by the favorable responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis treated with the interleukin-1 receptor antagonist anakinra [25]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T43","span":{"begin":0,"end":286},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The possibility that IL-1 and related pro-inflammatory pathways could serve as therapeutic targets was demonstrated by the favorable responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis treated with the interleukin-1 receptor antagonist anakinra [25]."}

{"project":"2_test","denotations":[{"id":"32599813-32411313-60095080","span":{"begin":282,"end":284},"obj":"32411313"}],"text":"The possibility that IL-1 and related pro-inflammatory pathways could serve as therapeutic targets was demonstrated by the favorable responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis treated with the interleukin-1 receptor antagonist anakinra [25]."}